NCT01640964View on ClinicalTrials.gov

An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Compensated Cirrhosis and Portal Hypertension
Interventions
DRUG

Terlipressin acetate

IV bolus injection

DRUG

Serelaxin (RLX030)

Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours

Trial Locations (1)

EH16 4TJ

Novartis Investigative Site, Edinburgh

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY